FyMed, Inc.

Press Releases
FY103B

FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract

Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...

FyMed Announces Top-Line Results Demonstrating Superiority of FY103B over Celecoxib in the Treatment of Pain and Inflammation

FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety. Read More...